New daratumumab Phase 2 results posted in stage 3B AL amyloidosis; AFT-19 results still standingNov 13Weekly roundup, 5 itemsapalutamidedaratumumabUpdated
FDA approves nivolumab for adjuvant Stage IIB/C melanoma treatmentNov 10Regulatory decisionBristol Myers Squibbnivolumab
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Regeneron registers Phase 3 LINKER-AL1 trial of linvoseltamab for AL amyloidosisOct 30Weekly roundup, 6 itemscemiplimab-rwlcdupilumabUpdated
Janssen registers Phase 3 TRIlogy-6 trial in newly diagnosed multiple myelomaOct 30Weekly roundup, 5 itemsbosentandaratumumab
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
J&J reports Q3 2026 results, raises full-year sales and EPS guidanceOct 13Quarterly updateJohnson & Johnson
AbbVie registers Phase 3 trial of etentamig vs Dara-CyBorD in AL amyloidosisAug 28Trial updateAbbViedexamethasone
C4 Therapeutics reports Q2 2026 results, cemsidomide trials on track for 2027 dataAug 11Quarterly updateC4 Therapeutics, Inc.cemsidomide
SunRISe-1 bladder cancer trial posts Phase 2b results; TiTan myeloma trial registeredJul 31Weekly roundup, 2 itemsdaratumumabJohnson & Johnson
Nexcella registers Phase 3 NEXICART-3 trial of CAR-T NXC-201 in AL amyloidosisJul 16Trial updateImmix Biopharma, Inc.
J&J raises 2026 sales and EPS guidance after strong Q2 resultsJul 15Quarterly updateJohnson & Johnson
Karuna/BMS opens Phase 3 KarXT relapse prevention trial in schizophreniaJul 7Weekly roundup, 2 itemsBristol Myers Squibbpomalidomide
AstraZeneca posts Phase 3 LOGOS, KALOS asthma results; updates Soliris labelJul 2Weekly roundup, 5 itemsAstraZenecaAZD4045